Latest News

Share buy-back update puts Aristocrat Leisure in focus Aristocrat Leisure (ASX:ALL) has updated the market on its on-market share buy-back, reporting cumulative repurchases of more than 22 million ordinary shares as of 31 March, under its ongoing capital management program. See our latest analysis for Aristocrat Leisure. The latest buy-back update lands as the 1-day share price return of 2.98% contrasts with a 90-day share price decline of 19.77% and a 1-year total shareholder return of...

Investors were disappointed by ALT Co., Ltd.'s ( KOSDAQ:459550 ) latest earnings release. We did some further digging...

Recent commentary on Gold.com highlights how gold’s traditional role as a haven asset held firm despite a sharp price drop during the Middle East conflict, when liquidity needs temporarily pushed prices lower. The analysis points out that investors are now rebuilding gold exposure as concerns over global debt, currency debasement, and geopolitical risks persist, supporting renewed attention on the metal. We’ll now explore how persistent geopolitical and macroeconomic risks highlighted by...

Zai Lab announced in the past that it will collaborate with Amgen on a global Phase 1b trial combining Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan with Amgen’s IMDELLTRA for patients with extensive-stage small cell lung cancer. Separately, the FDA’s identification of dozens of Tavneos-linked liver injury cases, including severe events and deaths, raises fresh questions about Amgen’s safety and regulatory risk profile. Next, we’ll explore how the FDA’s Tavneos safety concerns could...

Oncolytics Biotech (NasdaqCM:ONCY) has completed its domestication from Canada to the United States. The company has relocated its headquarters to San Diego, with the move now effective. Oncolytics Biotech is now classified as a U.S. domestic issuer under the U.S. regulatory framework. The domestication is intended to support operational efficiencies and access to U.S. capital markets. For you as an investor, this shift touches on both regulation and capital access. Oncolytics Biotech is an...

Duke Energy (NYSE:DUK) has completed the sale of its Tennessee Piedmont Natural Gas business to Spire. The company plans to use the proceeds to support its regulated capital investment plan over the next five years. The move marks a shift in Duke Energy's portfolio toward grid and generation projects while aiming to manage customer costs. Duke Energy, trading at about $130.9 per share, is using this transaction to refine where its capital is focused. The company has delivered an 11.5%...

Coca-Cola plans a long term investment of $1 billion in South Africa to expand production and distribution capacity. The company is acquiring a majority stake in Coca-Cola Beverages Africa, covering South Africa and 14 additional African markets. The investment focuses on local hiring, operational expansion and deeper integration with regional partners over multiple years. Coca-Cola (NYSE: KO) is adding a major Africa focused chapter to its global story with this $1 billion commitment. The...

Barrick Mining (TSX:ABX) is back in focus after quarterly results showed higher gold production, lower costs, favorable commodity prices, and record cash flow, along with increased share repurchases, a higher dividend, and a new operational review. See our latest analysis for Barrick Mining. The share price reaction has been sharp, with a 3.24% 1 day and 8.85% 7 day share price return after results. This comes even though the 30 day share price return shows a 15.15% decline and the year to...

BHP Group has recently advanced its copper and potash focus, including lodging the Escondida New Concentrator for environmental assessment, progressing the Resolution Copper project in the U.S., and increasing planned FY26 capex to US$11.00 billion across copper, iron ore and potash. At the same time, governments building strategic mineral reserves and BHP’s large Jansen potash development in Canada highlight how critical minerals policy and long-life projects are increasingly shaping the...

Wondering if Aegon shares are giving you enough value for the risk you are taking, especially after a strong multi year run? The stock last closed at €6.39, with returns of 3.5% over 7 days, 0.9% over 30 days, negative 3.7% year to date, 11.0% over 1 year, 91.4% over 3 years, and 101.8% over 5 years. Recent headlines around Aegon have focused on its position within the insurance sector and how its capital strength, business mix, and exposure to different markets compare with peers. This...

Laopu Gold (SEHK:6181) has drawn fresh attention after reporting full year 2025 results, issuing first quarter 2026 guidance, proposing higher final dividends, and flagging amendments to its articles of association. See our latest analysis for Laopu Gold. Laopu Gold’s latest earnings, dividend proposal and first quarter guidance arrive after a mixed share price run, with a 5.3% 90 day share price return but a 16.6% 1 year total shareholder return decline from the latest HK$650.5 level. If...

Last week's earnings announcement from LX Holdings Corp. ( KRX:383800 ) was disappointing to investors, with a sluggish...

In recent weeks, Simply Good Foods has faced mounting concerns as Atkins brand sales declined in consecutive quarters and rising costs pressured margins, prompting scrutiny of its growth outlook. Beyond the immediate slowdown, the key question now is whether stronger brands like Quest and OWYN can offset Atkins’ weakness and reshape the company’s long-term earnings mix. We’ll now examine how Atkins’ sales slump and margin pressure affect Simply Good Foods’ existing investment narrative built...

If you are wondering whether Alibaba Group Holding's share price offers value right now, or if the market is pricing it fairly, this breakdown will help you connect the current price with what the business may be worth. The stock last closed at US$123.73, with returns of a 4.7% decline over 7 days, a 13.2% decline over 30 days, a 20.6% decline year to date and a 3.1% decline over the past year, set against a 32.1% gain over 3 years and a 42.2% decline over 5 years. Recent headlines around...

Cirrus Aircraft (SEHK:2507) is drawing fresh attention after reporting full year 2025 results, with sales of US$1,354.37 million, net income of US$138.88 million, and a proposed final dividend of US$0.12 per share. See our latest analysis for Cirrus Aircraft. The latest earnings and dividend proposal have arrived during a weak patch for the shares, with a 1 month share price return showing a 39.93% decline and a 1 year total shareholder return showing a 6.9% decline, while a 1 day gain of...

In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76. The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs...

Novartis (SWX:NOVN) is back in focus after recent share price moves, with the stock showing mixed returns over the past month and past 3 months. This puts current valuation and fundamentals under the spotlight for investors. See our latest analysis for Novartis. The recent share price pullback, with a 1 month share price return of a 5.5% decline after a stronger 3 month share price return of 12%, comes against a backdrop of stronger long term total shareholder returns of 30.7% over 1 year and...

Abbott Laboratories (ABT) just expanded its cancer diagnostics reach through a new integration with Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers streamlined access to its Precision Oncology testing portfolio. See our latest analysis for Abbott Laboratories. Despite the oncology integration and other recent moves such as the ESOP related shelf registration and investment in Whoop, Abbott’s 30 day share price return of 10.29% and year to date share price return of...

Planet Labs PBC (PL) is back in focus after filing a US$680.7m shelf registration tied to an ESOP related offering, alongside fresh quarterly results, wider net losses, and new revenue guidance. See our latest analysis for Planet Labs PBC. After the shelf filing and earnings release, Planet Labs PBC’s 1-day share price return of 9.87% contrasts with a 7-day share price return of negative 13.18%. A 90-day share price return of 55.73% sits alongside a 1-year total shareholder return of about...

The subdued market reaction suggests that APT Electronics Co., Ltd.'s ( HKG:2551 ) recent earnings didn't contain any...

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...

Japan Hotel REIT Investment (TSE:8985) has drawn fresh attention after arranging new loans totaling ¥15.0b to refinance upcoming maturities, and reporting February 2026 revenue of ¥6,099m and year-to-date revenue of ¥11,966m. See our latest analysis for Japan Hotel REIT Investment. At a share price of ¥76,600, Japan Hotel REIT Investment has seen a 1 day share price return of 2.54%, while the 1 year total shareholder return is 13.18%. This suggests longer term holders have fared better than...

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...